DWTX$1.56
$1.64
Chart
Performance
Key Stats
AI DWTX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldZynerba Pharmaceuticals (ZYNE) presents a mixed investment profile. While its focus on rare neuropsychiatric conditions offers thematic potential, current financial performance and market sentiment suggest a 'Hold' rating. Investors should monitor clinical trial progress and regulatory developments closely.
Thematic
ZYNE operates in the niche but potentially high-growth area of cannabinoid therapies for rare neuropsychiatric disorders. The success of its lead product, Zygel, is key to its thematic appeal.
Fundamental
Zynerba Pharmaceuticals exhibits significant financial challenges, including negative earnings, lack of revenue, and a high cash burn rate. Its balance sheet is relatively clean with no outstanding debt, but overall financial health is precarious.
Technical
Technical indicators for ZYNE present a mixed picture. While some moving averages suggest a slight bullish trend, oscillators indicate overbought conditions and a potential for a short-term pullback.
| Factor | Score |
|---|---|
| Rare Disease Focus | 70 |
| Cannabinoid Therapies | 65 |
| Product Pipeline (Zygel) | 55 |
| Factor | Score |
|---|---|
| Valuation | 10 |
| Profitability | 5 |
| Growth | 0 |
| Balance Sheet Health | 70 |
| Cash Flow | 15 |
| Factor | Score |
|---|---|
| Trend Analysis | 50 |
| Momentum | 45 |
| Volume Confirmation | 50 |
| Support & Resistance | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (5)
Strong Cash Position
As of Q4 2024, the company has $14.85 million in cash equivalents, indicating sufficient liquidity. The ratio of cash to debt is 0.95, suggesting a manageable debt burden relative to available cash.
Positive Short-Term Performance
The stock has shown positive returns over shorter periods, with a 5-day performance of 1.71% and a 1-month performance of 1.27%.
Bearish Points (7)
Negative Earnings and Revenue
The company has reported zero revenue for multiple periods. Earnings Per Share (EPS) is significantly negative (e.g., -19.29 TTM, -4.19 in Q2 2025), indicating a lack of profitability. The Price-to-Earnings (P/E) ratio is negative or undefined, making traditional valuation difficult.
Increasing Debt Levels
Debt has increased from $0 in Q4 2023 to $15.59 million in Q4 2024. While cash equivalents are substantial, the rapid increase in debt for a company with no revenue raises concerns about future financial stability.
Calendar
August 2025
6
Next Earnings Date
H: $
A: $
L: $
Profile
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for burn and ocular pain; and IMC-2, a combination of valacyclovir and celecoxib in Phase 2 clinical trial for the treatment of long-COVID and post-acute sequelae of COVID-19 infection. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was incorporated in 2012 and is based in Alpharetta, Georgia.
Seasonals
Price Target
17.00 USD
The 39 analysts offering 1 year price forecasts for DWTX have a max estimate of 30.00 and a min estimate of 10.00.